Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by wildbird1on Aug 26, 2023 12:45pm
235 Views
Post# 35606752

RE:RE:New Deal for Adstiladrin

RE:RE:New Deal for Adstiladrin
enriquesuave wrote: Basically paying upfront  $500 Million for 5.1% and up to 8 % of sales of Adstiladrin over next 10 years or so.  That means they expect sales of up to $1 Billion per year.  Crazy, our turn will hopefully come soon.


enriquesuave, very good catch.

Let's see the difference between Adstiladrin & Ruvidar(TLD-1433).

CR%...
Adstiladrin 24%CR at 12 months.
Ruvidar 36%CR(and increasing) at 12 months.

Cost...
Adstiladrin for one year treatment cost $268kUS($364kCan).
Ruvidar cost $200k.US($300k.Can) for a one and done treatment.
For BCG-Resistant patients(and doctors) the choice will be easy.

enriquesuave you said " TLT should get double" I say double is a minimum.

In conclusion;
$500 millionUS for a treatment(Adstiladrin) that has a lower efficacy and cost more than Ruvidar.

I salivate at the idea of a big pharma deal for Ruvidar.


<< Previous
Bullboard Posts
Next >>